



Publikationen 2007 – 2009
Klinik für Internistische Onkologie
an der Klinik für Tumorbiologie

Prof. Dr. C. Unger

Originalarbeiten

1. B. Hildenbrand, B. Sauer, O. Kalis, C. Stoll, M.A. Freudenberg, G. Niedermann, J.M. Giesler, E. Jüttner, J.H. Peters, B. Häring, R. Leo, C. Unger, M. Azémar:
Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with Interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells – a pilot study.
The Prostate 67, 500-508 (2007)
2. K. Mross, S. Steinbild, F. Baas, D. Gmehling, M. Radtke, D. Voliotis, E. Brendel, O. Christensen, C. Unger:
Results from an in vitro and a clinical/pharmacological phase-I-study with the combination Irinotecan and Sorafenib.
Eur. J. Cancer 43, 55-63 (2007)
3. F. Kratz, G. Ehling, H.-M. Kauffmann, C. Unger:
Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of Doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent Doxorubicin.
Human & Experimental Toxicology 26, 19-35 (2007)
4. C. Bornmann, R. Graeser, N. Esser, V. Zirolì, P. Jantscheff, T. Keck, C. Unger, U.T. Hopt, U. Adam, C. Schaechtele, U. Massing, E. von Dobschuetz:
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
Cancer Chemother. Pharmacol. (2007)
5. J. Drevs, P. Siegert, M. Medinger, K. Mross, R. Strecker, U. Zirrgiebel, J. Harder, H. Blum, J. Robertson, J. Jürgenmeier, T. Puchalski, H. Young, O. Saunders, C. Unger:
Phase-I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Journal of Clinical Oncology 25, 3045-3054 (2007)
6. L.A. Taylor, J. Arends, A.K. Hodina, C. Unger, U. Massing:
Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status.
Lipids in Health and Disease, 6-17 (2007)
7. S. Steinbild, J. Arends, M. Medinger, B. Häring, A. Frost, J. Drevs, C. Unger, R. Strecker, J. Hennig, K. Mross:
Metronomic anti-angiogenic therapy with capecitabine and celecoxib (CC) in advanced tumor patients – results of a phase-II-study.
Oncology 30, 629-635 (2007)
8. M. Azemar, B. Hildenbrand, B. Häring, E. Heim and C. Unger:
Clinical benefit in patients with advanced solid tumors treated with modified citrus pectin: a prospective pilot study.

- Clinical Medicine: Oncology: I 73-80 (2007)
9. C. Unger, B. Häring, M. Medinger, J. Drevs, S. Steinbild, F. Kratz, K. Mross:
Phase I and pharmacokinetic study of the (6-Maleimidocaproyl) hydrazone derivative of Doxorubicin.
Clin. Cancer Res. 13(16), 4858-4866 (2007)
 10. R. Graeser, D-E. Chung, N. Esser, S. Moor, Chr. Schächtele, C. Unger, F. Kratz:
Synthesis and biological evaluation of an Albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model. (LNCAP).
Int. J. Cancer 122, 1145-1154 (2008)
 11. B. Hildenbrand, D. Lorenzen, B. Sauer, Ch. Hertkorn, M.A. Freudenberg, J.H. Peters, Th. Nesselhut, C. Unger, M. Azemar:
IFN- γ enhances T_H1 polarisation of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions.
Anticancer Research 28, 1467-1476 (2008)
 12. J. Soltau, U. Zirrgiebel, N. Esser, Ch. Schächtele, F. Totzke, C. Unger, I. Merfort, J. Drevs:
Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
Anticancer Res. 28: 933-942 (2008)
 13. C. Unger, A. Musch:
Lapatinib: Neue Option beim fortgeschrittenen oder metastasierten ErbB2/Her2-überexprimierenden Brustkrebs.
Arzneimitteltherapie, 26. Jahrgang, Heft 11, 395-400 (2008)
 14. C. Unger:
Diagnostik und Behandlung von Knochenmetastasen.
Ärztliche Praxis Onkologie, 1, 32-33 (2009).
 15. P. Jantscheff, V. Ziroli, N. Esser, R. Graeser, J. Kluth, A. Sukolinskaya, L.A. Taylor, C. Unger, U. Massing:
Anti-metastatic effects of liposomal Gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.
Clin. Exp. Metastasis 26, 981-992 (2009)
 16. B. Müller-Hübenthal, M. Azemar, D.R. Lorenzen, M. Huber, M.A. Freudenberg, Chr. Galanos, C. Unger, B. Hildenbrand:
Tumour biology: Tumour-associated inflammation versus antitumor immunity.
Anticancer Research 29, 4795-4806 (2009)
 17. R. Gräser, N. Esser, H. Unger, C. Unger, F. Kratz :
INNO-206 shows superior antitumor efficacy compared to doxorubicin in an orthotopic pancreas carcinoma model, Proc. Amer. Assoc. Cancer Res. 50, 3660 (2009)

18. M.HG. Langenberg, C.ML van Herpen, J. De Bono, J.HM Schellens, C. Unger, K. Hoekman, H.E. Blum, W. Fiedler, J. Drevs, F. Le Maulf, A. Fielding, J. Robertson, E.E. Voest:
Effective strategies for management of hypertension following VEGF signaling inhibition therapy: results from a phase-II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
JCO 10, 2273-2279 (2009) L.A. Taylor, L. Pletschen, J. Arends, C. Unger, U. Massing:
Marine phospholipids - a promising new dietary approach to tumor-associated weight loss.
Supportive Care Cancer 18(2), 159-170 (2010)
19. K. Mross, M. Stefanic, D. Gmehling, A. Frost, F. Baas, C. Unger, R. Strecker, J. Hennig, B. Gaschler-Markefski, P. Stopfer, L. de Rossi, R. Kaiser:
Phase-I-study of the triple angiogenesis inhibitor BIBF 1120 in patients with metastatic solid tumors.
Clinical Cancer Research 16, 311-319 (2010)
20. C. Unger, W.E. Berdel, A.-R. Hanauske, H. Sindermann, J. Engel, K. Mross:
First-time-in-man and pharmacokinetic study of weekly oral Perifosine in patients with solid tumors.
EJC 38, 12: 1615-1621 (2010)
21. J. Drevs, M. Medinger, K. Mross, J. Hennig, M. Buechert, W. Stewart, C. Unger:
A Phase IA, open-label, dose-escalating study of PTK787/ZK 22284 administered orally on an ongoing once daily schedule in patients with advanced cancer.
EJC (in press, 2010)
22. S. Steinbild, A. Frost, B. Häring, C. Unger, K. Mross:
Phase-II-study with 3rd or 4th line Bendamustin (flat dose) therapy in patients with metastatic breast cancer.
(submitted)

Buchbeiträge

1. C. Unger:
Krebs Auge zum Abgrund: Das Leben ist das höchste Gut.
Flensburger Hefte 103, 2009.
2. C. Unger:
Onkologie: Antiangiogenese-Analoga.
Ecomed Verlag, Zeller, zur Hausen Hrsg., 2009.

Abstracts

1. CML van Herpen, J. Dreves, H. van Crujisen, E.E. Voest, C.J. Punt, J. Robertson, O. Saunders, U. Zirrgiebel, C. Unger, G. Giaccone:
Evaluation of AZD2171, an oral highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma: combined results from two Phase-I-studies.
Abstract, ASCO, Illinois, 2007.
2. B. Hildenbrand, M. Azemar, B. Sauer, M. Zimmermann, S.F. Martin, M. Huber, D. Lorenzen, C. Unger, M.A. Freudenberg, C. Galanos:
In-vitro-maturation of human monocyte-derived dendritic cells in presence of acid-treated gram-negative bacteria (R- and S-form) under serum-free conditions.
Poster, 5th Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) with the 3rd International Conference "Strategies for Immune Therapy" (SFIT): University of Würzburg; April 12-14, 2007.
3. B. Hildenbrand, M. Azemar, B. Sauer, F. Neumann, M. Zimmermann, C. Unger, M.A. Freudenberg, C. Galanos:
In-vitro maturation of human monocyte-derived dendritic cells with highly purified LPS-preparations from *Salmonella minnesota* R-mutants under serum-free conditions.
Poster, Death, Danger and Immunity: Institute Pasteur, Paris; March 8-9, 2007.
4. M. Füllbrand, B. Sauer, M. Zimmermann, D. Lorenzen, S.F. Martin, M.A. Freudenberg, C. Galanos, C. Unger, B. Hildenbrand, M. Azemar:
The presence of IFN- γ enhances Type-1 polarization of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions.
Poster, 4th International Symposium on the Clinical Use of Cellular Products, Cellular Therapy: University of Regensburg; March 22-23, 2007.
5. B. Hildenbrand, M. Azemar, B. Sauer, M. Zimmermann, S.F. Martin, M. Huber, D. Lorenzen, C. Unger, M.A. Freudenberg, C. Galanos:
In vitro maturation of human monocyte-derived dendritic cells with highly purified LPS-preparations from *Salmonella minnesota* under serum-free conditions.
Poster, 4th International Symposium on the Clinical Use of Cellular Products, Cellular Therapy: University of Regensburg; March 22-23, 2007.
6. B. Hildenbrand, M. Azemar, B. Sauer, M. Zimmermann, S.F. Martin, M. Huber, D. Lorenzen, C. Unger, M.A. Freudenberg, C. Galanos:
Highly purified R-form LPS from *Salmonella* in combination with IFN- γ enhance maturation and DC₁-polarisation of human monocyte-derived dendritic cells under serum-free conditions. CIMT-Kongress 04/2007.
Poster, 5th Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) with the 3rd International Conference "Strategies for Immune Therapy" (SFIT): University of Würzburg; April 12-14, 2007.

7. B. Hildenbrand, M. Azemar, B. Sauer B, F. Neumann, M. Zimmermann , C. Unger, M.A. Freudenberg, C. Galanos:
In-vitro maturation of human monocyte-derived dendritic cells with highly purified LPS-preparations from Salmonella minnesota R-mutants under serum-free conditions.
Poster Death, Danger and Immunity: Institute Pasteur, Paris; March 8-9, 2007.
8. S. Hedbom, S. Steinbild, A. Frost, M. Büchert, C. Unger, O. Christensen, M. Kornacker, D. Voliotis, R. Heinig, K. Mross:
Phase-I-study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors.
Abstract ASCO, Chicago, Illinois, 2007.
9. A. Frost, A., S. Hedbom, S. Steinbild, M. Büchert, C. Unger, O. Christensen, O., D. Voliotis, R. Heinig, K. Mross:
Phase-I-study of BAY 73-4506, a kinase inhibitor that targets oncogenic and angiogenic kinases, in patients with advanced solid tumors.
Abstract AACR-NCI-EORTC-Kongress San Francisco/USA, 2007.
10. A. Frost, M. Büchert, C. Unger, O. Christensen, A. Wagner, R. Heinig, M. Scheulen, D. Strumberg, K. Mross:
Phase-I-study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: final results of a dose escalation study.
Abstract ASCO, Chicago, Vol. 26, No 15S Part I, 2008.
11. M. Langenberg, C.M van Herpen, J. De Bono, C. Unger, J.H.M. Schellens, K. Hoekman, H.E. Blum, F. Le Maulf, A. Fielding.L., E.E. Voest.
Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: a randomized phase-II-study of Cediranib.
Abstract ASCO, Chicago, Vol. 26, No 15S Part I, 2008.
12. C. Müller, S. Al-Batran, E. Jäger, B. Schmidt, M. Bausch, C. Unger, N. Sethuraman:
A phase-IIa-study of PEGylated Glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors.
Abstract ASCO, Chicago, Vol. 26, No 15S, Part I, 2008.
13. B. Hildenbrand, F. Neumann, DR Lorenzen, B. Sauer, SF Martin, M. Huber, C. Unger, MA Freudenberg, C. Galanos, M. Azemar:
Human monocyte-derived dendritic cells mature under serum-free conditions with a strong T_H1-polarisation using novel highly purified endotoxin preparations as TLR4-agonists.
10th Biennial Meeting of the International Endotoxin and Innate Immunity Society, Wednesday 30th July – Saturday 2nd August 2008, Appleton Tower, Edinburgh University, Scotland, United Kingdom, 2008.
14. R. Graeser, N. Esser, A. Schillert, B. Hildenbrand, C. Unger, C. Schaechtele:
Development of an orthotopic colon tumor model using HT29 cells with an endogenous population of CD133/CD44 positive cells.
AACR Annual Meeting, San Diego, CA, April 12-14, 2008.

15. B. Hildenbrand, F. Neumann, D.R. Lorenzen, V. Küttner, M. Gummenscheimer, S.F. Martin, M. Huber, C. Unger, M.A. Freudenberg, C. Galanos, M. Azemar:
In vitro maturation of human monocyte-derived dendritic cells under serum-free conditions in the presence of acid-treated gram-negative bacteria Loaded with prostate specific antigen.
Abstract, 8th International Conference of Anticancer Research 17-22 October, 2008.
16. B. Hildenbrand, F. Neumann, M. Azemar, U. Massing, C. Unger, K. Mross:
Detection of therapy-induced tumour death biomarkers in patient serum samples.
Abstract, 8th International Conference of Anticancer Research 17-22 October, 2008.
17. B. Hildenbrand, D.R. Lorenzen, F. Neumann, B. Sauer, R. Graesser, L.A. Taylor, V. Küttner, M.A. Freudenberg, C. Galanos, Massing U, C. Unger, M. Azemar:
2-Hydroxy-Octadecylphosphocholine enhances CD83 expression of human monocyte-derived dendritic cells matured with LPS and IFN- γ inhibiting cytokine secretion without affecting T_H1 polarisation.
Abstract, 8th International Conference of Anticancer Research 17-22 October, 2008.
18. B. Hildenbrand, F. Neumann, DR Lorenzen, B. Sauer, SF Martin, M. Huber, C. Unger, MA Freudenberg, C. Galanos, M. Azemar:
Human monocyte-derived dendritic cells mature under serum-free conditions with a strong T_H1-polarisation using novel highly purified endotoxin preparations as TLR4-agonists.
Abstract 1st International Conference on Immunochemotherapy in Paris 17-18 October, 2008.
19. R. Graeser, N. Esser, H. Unger, C. Unger, F. Kratz:
INNO-206 shows superior antitumor efficacy compared to Doxorubicin in an orthotopic pancreas carcinoma model.
Abstract AACR-Meeting, 2009.
20. B. Elsadek, N. Esser, R. Graeser, A. Warnecke, C. Unger, T. Saleem, F. Kratz:
Evaluation of a PSA cleavable prodrug in the in vitro and in vivo LNCaP LN model:
Abstract AACR-Meeting, Washington, 2010.

Dissertationen und Diplomarbeiten

1. B. Schmid:
Albuminbindende, enzymatisch spaltbare Camptothecin-Derivate - antitumoral wirksame Prodrugs für eine effizientere Chemotherapie.
Universität Freiburg 2007 (Chem. Diss.)
2. A. Sukalinskaya:
Verbesserung der Wirkung von Gemcitabin an Prostata-Ca-Zellen in vitro und in vivo durch liposomalen Einschluss.
Universität Freiburg, 2007 (Med. Diss.)
3. Chr. Bornmann:
Wirksamkeitsnachweis einer neuen liposomalen Gemcitabin-Formulierung auf humane Pankreaskarzinome durch Biolumineszenz-Imaging.
Universität Freiburg, 2007 (Med. Diss.)
4. M. Zimmermann:
Optimierung der Antigen-spezifischen Induktion zytotoxischer T-Zellen durch in serumfreiem Medium gereifte und unterschiedlich mit Antigenen beladene humane myeloide dendritische Zellen.
Universität Freiburg, 2007 (Biol. Diss.)
5. S. Wick:
Untersuchungen zur Wirkung von Granatapfelsaft auf Parameter des oxidativen Stresses im Menschen.
Master's Thesis im Studiengang Ernährungswissenschaft der TU München an der Klinik für Tumorbiologie in Freiburg, 2007.
6. A. Walter:
Optimierung der Maturierung humaner myeloider dendritischer Zellen mit TLR-4-Agonisten unter Interferon- γ -unter klinikkonformen Bedingungen.
Universität Freiburg, 2008 (Med. Diss.)
7. V. Küttner:
Untersuchungen zur Induktion einer antitumoralen Immunität durch unter serumfreien Bedingungen optimiert gereifte und T_H1 polarisierte humane dendritische Zellen.
Universität Freiburg, 2009 (Biol. Diss.)
8. M. Füllbrandt:
Untersuchungen zur Reifung humaner, myeloider dendritischer Zellen mit R- und S-Form-Lipopolysacchariden unter serumfreien Bedingungen.
Universität Freiburg, 2009 (Med. Diss.)